-
公开(公告)号：US11872225B2
公开(公告)日：2024-01-16
申请号：US17586777
申请日：2022-01-27
发明人： Giovanni Cianchetta , Charles Kung , Tao Liu , Anil Kumar Padyana , Zhihua Sui , Zhenwei Cai , Dawei Cui , Jingjing Ji
IPC分类号： C07D513/14 , A61K31/5025 , A61K31/506 , A61K31/519 , C07D241/36 , A61K45/06
CPC分类号： A61K31/5025 , A61K31/506 , A61K31/519 , C07D241/36 , C07D513/14 , A61K45/06
摘要： Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I):
wherein R1, R2, L1, and L2 are as defined herein.-
公开(公告)号：US11718642B2
公开(公告)日：2023-08-08
申请号：US16961097
申请日：2019-01-11
发明人： Albert Jean Robichaud , Francesco G. Salituro , Maria Jesus Blanco-Pillado , Daniel La , Boyd L. Harrison
IPC分类号： A61K31/352 , A61K31/382 , A61K31/385 , A61K31/39 , A61K31/435 , A61K31/498 , A61K31/502 , A61K31/517 , A61K31/53 , A61K31/536 , A61K31/415 , C07D221/08 , C07D237/26 , C07D239/70 , C07D241/36 , C07D253/08 , C07D265/02 , C07D265/12 , C07D265/34 , C07D279/02 , C07D279/08 , C07D279/14 , C07D291/08 , C07D311/78 , C07D319/02 , C07D319/08 , C07D319/14 , C07D323/04 , C07D327/06 , C07D327/10 , C07D335/04 , C07D339/08 , C07D341/00 , C07D401/06 , C07D405/14 , C07D407/14 , C07D409/14 , C07D411/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07J73/00
CPC分类号： C07J73/003
摘要： Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g. in the treatment of CNS-related disorders.
-
公开(公告)号：USRE48992E1
公开(公告)日：2022-03-29
申请号：US16670784
申请日：2019-10-31
发明人： Marcus Conrad , Joel Schick , Bettina Proneth , Peter Sennhenn
IPC分类号： C07D495/10 , A61K31/498 , A61K31/499 , A61K31/55 , A61K31/5513 , C07D241/36 , C07D241/42 , C07D403/12 , C07D413/06 , C07D471/10 , C07D487/10 , C07D491/06 , C07D491/107
摘要： The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.
-
公开(公告)号：US11279680B2
公开(公告)日：2022-03-22
申请号：US16471980
申请日：2018-01-09
IPC分类号： C07D241/36 , C07D401/10 , C07D403/10 , C07D413/10 , C09K11/06 , H01L51/00 , H01L51/50 , C07D401/14
摘要： Provided are: a dicyano N-heterocyclic compound represented by formula (I) (in the formula, R3 represents an electron-donating group, and n represents the number of repetitions of the content in brackets and is 0 or 1), the compound having exceptional heat resistance and light emission characteristics; a light-emitting material; and a light-emitting element in which the same is used.
-
公开(公告)号：US11069861B2
公开(公告)日：2021-07-20
申请号：US17077493
申请日：2020-10-22
发明人： Ryoji Maeda , Tasuku Haketa , Kazuki Nishimura , Masato Nakamura
IPC分类号： H01L51/00 , C07C13/08 , C07D221/18 , C07D241/36
摘要： A mixture contains a first compound and a second compound, in which the first compound has at least one of a first cyclic structure represented by a formula (11) below and a second cyclic structure represented by a formula (12) below, and the second compound is a compound represented by a formula (21) or a compound represented by a formula (22) below, and a total mass MT of the first and second compounds and a mass M2 of the second compound in the mixture satisfy a relationship of a numerical formula (Numerical Formula 1) below,
-
公开(公告)号：US11040036B2
公开(公告)日：2021-06-22
申请号：US16952257
申请日：2020-11-19
发明人： Giovanni Cianchetta , Tao Liu , Anil Kumar Padyana , Zhihua Sui , Zhenwei Cai , Dawei Cui , Jingjing Ji
IPC分类号： A61K31/5025 , A61K31/506 , A61K31/519 , A61K45/06 , C07D241/36 , C07D513/14
摘要： Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
-
7.发明申请公开(公告)号：US20190330162A1
公开(公告)日：2019-10-31
申请号：US16471980
申请日：2018-01-09
IPC分类号： C07D241/36 , H01L51/00 , H01L51/50 , C07D403/10 , C07D413/10 , C07D401/14
摘要： Provided are: a dicyano N-heterocyclic compound represented by formula (I) (in the formula, R3 represents an electron-donating group, and n represents the number of repetitions of the content in brackets and is 0 or 1), the compound having exceptional heat resistance and light emission characteristics; a light-emitting material; and a light-emitting element in which the same is used.
-
公开(公告)号：US10280179B2
公开(公告)日：2019-05-07
申请号：US15707729
申请日：2017-09-18
发明人： Marcus Conrad , Joel Schick , Bettina Proneth , Peter Sennhenn
IPC分类号： A61K31/55 , A61K31/498 , A61K31/499 , C07D241/36 , C07D241/42 , C07D403/12 , C07D413/06 , C07D417/10 , C07D487/10 , C07D491/06 , C07D495/10 , A61K31/5513 , C07D491/107 , C07D471/10
摘要： The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterized by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterized by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterized by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.
-
公开(公告)号：US20190008858A1
公开(公告)日：2019-01-10
申请号：US16005111
申请日：2018-06-11
发明人： Kyla Bjornson , Eda Canales , Jeromy J. Cottell , Kapil K. Karki , Ashley A. Katana , Darryl Kato , Tetsuya Kobayashi , John O. Link , Ruben Martinez , Barton W. Phillips , Hyung-jung Pyun , Michael Sangi , Adam J. Schrier , Dustin Siegel , James G. Taylor , Chinh V. Tran , Teresa A. Trejo Martin , Randall W. Vivian , Zheng-Yu Yang , Jeff Zablocki , Sheila Zipfel
IPC分类号： A61K31/498 , C07K5/08 , A61K31/10 , C07K5/083 , C07D498/22 , C07D498/16 , C07D403/14 , C07D241/36 , A61K45/06 , A61K38/21 , A61K38/06 , C07K5/087 , A61K31/519 , A61K31/506 , A61K31/4985 , A61K31/4745 , A61K31/401 , A61K38/00
CPC分类号： A61K31/498 , A61K31/10 , A61K31/401 , A61K31/4745 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K38/00 , A61K38/06 , A61K38/21 , A61K45/06 , C07D241/36 , C07D403/14 , C07D498/16 , C07D498/22 , C07K5/08 , C07K5/0808 , C07K5/0812 , C07K5/0827 , A61K2300/00
摘要： Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
-
公开(公告)号：US20180065982A1
公开(公告)日：2018-03-08
申请号：US15707729
申请日：2017-09-18
发明人： Marcus Conrad , Joel Schick , Bettina Proneth , Peter Sennhenn
IPC分类号： C07D495/10 , C07D241/42 , C07D491/06 , A61K31/498 , A61K31/499 , A61K31/55 , A61K31/5513 , C07D241/36 , C07D491/107 , C07D403/12 , C07D413/06 , C07D471/10 , C07D487/10
CPC分类号： C07D495/10 , A61K31/498 , A61K31/499 , A61K31/55 , A61K31/5513 , C07D241/36 , C07D241/42 , C07D403/12 , C07D413/06 , C07D471/10 , C07D487/10 , C07D491/06 , C07D491/107
摘要： The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.
-
-
-
-
-
-
-
-
-
搜索结果
564 条记录 (耗时 0.054 秒)
